ICU Medical will release Q2 2026 earnings on August 6, followed by a conference call at 4:30 p.m. ET.
Quiver AI Summary
ICU Medical, Inc., based in San Clemente, California, has announced its upcoming second quarter 2026 earnings release and conference call scheduled for August 6, 2026. The earnings results will be made public around 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET, accessible at 1-800-420-1459 with the conference ID “ICUMED.” Additionally, the call will be available via a live webcast on the company's website, which will also offer a replay afterward. ICU Medical is recognized for its innovative medical products, particularly in infusion systems and critical care products, serving various healthcare settings. Further information can be found on their website.
Potential Positives
- ICU Medical has announced the date and time for its second quarter 2026 earnings release, which demonstrates transparency and keeps investors informed.
- The scheduled conference call offers investors direct access to the company's financial results and management insights for Q2 2026.
- The webcast of the earnings call will be available for replay, ensuring that shareholders and analysts can review the information at their convenience.
Potential Negatives
- Announcement of earnings release dates could indicate potential financial troubles if results do not meet investor expectations.
FAQ
When will ICU Medical announce its Q2 2026 earnings?
ICU Medical will release its Q2 2026 results on Thursday, August 6, 2026, at approximately 4:00 p.m. ET.
What time is the Q2 2026 conference call?
The conference call regarding Q2 2026 results is scheduled for 4:30 p.m. ET on August 6, 2026.
How can I access the conference call?
You can access the conference call at 1-800-420-1459 using conference ID “ICUMED”.
Is there a webcast for the earnings call?
Yes, the call will be available by webcast on the ICU Medical website under the Investors tab.
Who can I contact for more information?
For more information, you can contact Brian Bonnell at ICU Medical at (949) 366-2183.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICUI Insider Trading Activity
$ICUI insiders have traded $ICUI stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ICUI stock by insiders over the last 6 months:
- VIRGINIA RUTH SANZONE (VP, General Counsel) sold 2,447 shares for an estimated $303,623
- DAVID C. GREENBERG sold 2,424 shares for an estimated $297,933
- DANIEL WOOLSON (President) sold 2,123 shares for an estimated $280,684
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ICUI Revenue
$ICUI had revenues of $530.2M in Q1 2026. This is a decrease of -12.32% from the same period in the prior year.
You can track ICUI financials on Quiver Quantitative's ICUI stock page.
You can access data on ICUI stock through the Quiver Quantitative API.
$ICUI Hedge Fund Activity
We have seen 116 institutional investors add shares of $ICUI stock to their portfolio, and 128 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- REINHART PARTNERS, LLC. added 314,768 shares (+inf%) to their portfolio in Q2 2026, for an estimated $46,144,988
- POINT72 ASSET MANAGEMENT, L.P. removed 254,575 shares (-75.4%) from their portfolio in Q1 2026, for an estimated $32,878,361
- TORONTO DOMINION BANK added 208,932 shares (+inf%) to their portfolio in Q1 2026, for an estimated $26,983,567
- MANUFACTURERS LIFE INSURANCE COMPANY, THE added 159,011 shares (+1394.0%) to their portfolio in Q1 2026, for an estimated $20,536,270
- THRIVENT FINANCIAL FOR LUTHERANS added 130,042 shares (+42.9%) to their portfolio in Q1 2026, for an estimated $16,794,924
- CITADEL ADVISORS LLC added 122,437 shares (+58.1%) to their portfolio in Q1 2026, for an estimated $15,812,738
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 119,862 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $15,480,177
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ICUI Price Targets
Multiple analysts have issued price targets for $ICUI recently. We have seen 4 analysts offer price targets for $ICUI in the last 6 months, with a median target of $164.5.
Here are some recent targets:
- Sam Eiber from BTIG set a target price of $170.0 on 06/15/2026
- Mike Matson from Needham set a target price of $165.0 on 05/27/2026
- Brett Fishbin from Keybanc set a target price of $164.0 on 04/27/2026
- Jason Bednar from Piper Sandler set a target price of $163.0 on 04/17/2026
Full Release
SAN CLEMENTE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2026 earnings release and conference call.
The Company will release its second quarter 2026 results on Thursday, August 6, 2026 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, August 6, 2026. The call can be accessed at 1-800-420-1459, conference ID “ICUMED”. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com , clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.
About ICU Medical
ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com .
CONTACT:
ICU Medical, Inc.
Brian Bonnell, Chief Financial Officer
(949) 366-2183
ICR, Inc.
John Mills, Managing Partner
(646) 277-1254
Source: ICU Medical, Inc.
